Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2012) 120 (21): 1901.

https://doi.org/10.1182/blood.V120.21.1901.1901

Published: 2012

Journal Articles

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Akira Kitanaka, MD, PhD, Akihiro Ihara, MD, PhD, Akira Sakai, MD, PhD, Yoshiaki Kuroda, MD, PhD, Hideki Asaoku, MD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2011) 118 (21): 885.

https://doi.org/10.1182/blood.V118.21.885.885

Published: 2011

Journal Articles

BMI1 Collaborates with RUNX1/AML1 Mutants in the Development of Human Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

Hironori Harada, MD, Ye Ding, MD, Jun Imagawa, MD, Takahiko Miyama, MD, Akiro Kimura, MD, Yuka Harada, MD

Blood (2011) 118 (21): 275.

https://doi.org/10.1182/blood.V118.21.275.275

Published: 2011

Journal Articles

Expansion of CD8 + /perforin + T-Cell Subset in Patients Predicts Response to Cyclosporin A Therapy in Patients with Erythroid Hypoplasia/Aplasia

Hideaki Nitta, MD, Yuka Harada, MD, Hideo Hyodo, MD, Akiro Kimura, MD, Hironori Harada, MD

Blood (2011) 118 (21): 1337.

https://doi.org/10.1182/blood.V118.21.1337.1337

Published: 2011

Journal Articles

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Joyeeta Bhattacharyya, Keichiro Mihara, MD, PhD, Motoaki Ohtsubo, Shin'ichiro Yasunaga, MD, PhD, Yoshihiro Takihara, MD, PhD, Masaharu Hoshi, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 3613.

https://doi.org/10.1182/blood.V116.21.3613.3613

Published: 2010

Journal Articles

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

Akira Sakai, MD, PhD, Miyo Oda, PhD, Noriaki Yoshida, MD, Mitsuhiro Itagaki, MD, Koji Arihiro, MD, PhD, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 2949.

https://doi.org/10.1182/blood.V116.21.2949.2949

Published: 2010

Journal Articles

AML1/RUNX1 Point Mutation Possibly Promotes Leukemic Transformation in Myeloproliferative Disorders.

Jun Imagawa, MD, Yuka Harada, MD, Ye Ding, MD, Akiro Kimura, MD, PhD, Hironori Harada, MD, PhD

Blood (2009) 114 (22): 1902.

https://doi.org/10.1182/blood.V114.22.1902.1902

Published: 2009

Journal Articles

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Yoshiaki Tomiyama, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD, Shinya Katsutani, MD, Akiro Kimura, MD, Yasushi Okoshi, MD, PhD, Haruhiko Ninomiya, MD, PhD, Hiroshi Kosugi, MD, PhD, Shosaku Nomura, MD, Katsutoshi Ozaki, MD, Yasuo Ikeda, MD, Nobuyuki Koh, Koichi Katsura, MD, PhD, Yuzuru Kanakura, MD, PhD

Blood (2009) 114 (22): 1324.

https://doi.org/10.1182/blood.V114.22.1324.1324

Published: 2009

Journal Articles

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, MD, Hirotaka Matsui, MD, PhD, Koji Arihiro, MD, PhD, Megumu Fujihara, MD, PhD, Takashi Nishisaka, MD, PhD, Naomi Sasaki, MD, PhD, Yoshito Sadahira, MD, PhD, Akiro Kimura, MD, PhD

Blood (2009) 114 (22): 2927.

https://doi.org/10.1182/blood.V114.22.2927.2927

Published: 2009

Journal Articles

Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in ATL

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Hideaki Nitta, MD, Takashi Nishisaka, MD, PhD, Akiro Kimura, MD, PhD

Blood (2008) 112 (11): 2817.

https://doi.org/10.1182/blood.V112.11.2817.2817

Published: 2008

Journal Articles

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Keichiro Mihara, MD, PhD, Kazuyoshi Yanagihara, PhD, Misato Takigahira, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD, PhD

Blood (2008) 112 (11): 2610.

https://doi.org/10.1182/blood.V112.11.2610.2610

Published: 2008

Journal Articles

Interferon-γ Attenuates the Survival Activity of G-CSF through PI3K/Akt Signaling Pathway in Mouse Multipotent Progenitor Cells.

Hong Liu, MD, PhD, Keichiro Mihara, MD,Ph.D, Hideo Tanaka, MD,Ph.D, Akiro Kimura, MD,Ph.D

Blood (2006) 108 (11): 4163.

https://doi.org/10.1182/blood.V108.11.4163.4163

Published: 2006

Journal Articles

Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.

Yoshiaki Kuroda, MD, Akira Sakai, MD, Naohiro Tsuyama, PhD, Mami Mizuno, Nanae Nakaju, Shoso Munemasa, MD, Yoshiko Okikawa, MD, Yuta Katayama, MD, Akiro Kimura, MD

Blood (2005) 106 (11): 3411.

https://doi.org/10.1182/blood.V106.11.3411.3411

Published: 2005

Journal Articles

Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.

Moniruddin Chowdhury, Keichiro Mihara, MD, Nanae Nakaju, Sachiko Fukumoto-Hidani, Yoshihiro Takihara, MD, Akiro Kimura, MD

Blood (2005) 106 (11): 3296.

https://doi.org/10.1182/blood.V106.11.3296.3296

Published: 2005

Journal Articles

IFNα Therapy Up-Regulates Serum Soluble TRAIL Levels and Induces Marked TRAIL mRNA Expressions in Polymorphonuclear Neutrophils in Chronic Myeloid Leukemia Patients.

Hideo Tanaka, MD, Takuo Ito, MD, Akiro Kimura, MD

Blood (2005) 106 (11): 2885.

https://doi.org/10.1182/blood.V106.11.2885.2885

Published: 2005

NARROW

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

BMI1 Collaborates with RUNX1/AML1 Mutants in the Development of Human Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

Expansion of CD8 + /perforin + T-Cell Subset in Patients Predicts Response to Cyclosporin A Therapy in Patients with Erythroid Hypoplasia/Aplasia

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

AML1/RUNX1 Point Mutation Possibly Promotes Leukemic Transformation in Myeloproliferative Disorders.

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in ATL

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Interferon-γ Attenuates the Survival Activity of G-CSF through PI3K/Akt Signaling Pathway in Mouse Multipotent Progenitor Cells.

Induction of Cyclin D1 Gene in Myeloma Cells Down-Regulates the Expression of Cyclin D2.

Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.

IFNα Therapy Up-Regulates Serum Soluble TRAIL Levels and Induces Marked TRAIL mRNA Expressions in Polymorphonuclear Neutrophils in Chronic Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only